Excess copper causes hepatocyte death in hereditary Wilson disease (WD). Current WD treatments by copper-binding chelators may gradually reduce copper overload; they fail, however, to bring hepatic copper close to normal physiological levels. Consequently, lifelong daily dose regimens are required to hinder disease progression. This may result in severe issues due to non-adherence or unwanted drug reactions, but also in drug switching and ultimate treatment failures.